Güler BERKİTEN, Tolgar Lütfi KUMRAL, Ziya SALTÜRK, Belgin TUTAR, Ayşe Enise GÖKER, Gürcan SÜNNETÇİ, YAVUZ UYAR, Hilmi UĞRAŞ

Koenzim Q10'un ratlarda sıçanlarda sisplatininneden olduğu ototoksisiteye etkisi

Amaç: Sıçanlarda düflük ve yüksek dozlarda koenzim Q10'un sistemikuygulamasının sisplatinin neden olduğu ototoksisite üzerine etkinliğinibelirlemek. Yöntem:Çalıflmamız 40 Sprague-Dawley sıçanla gerçeklefltirildi. Sıçanlar randomize flekilde befl gruba ayrıldı: Cis, Cis+Q1030, Cis+Q1010,Q10, kontrol. Cis (n=8) grubuna tek bir 14 mg/kg dozda intraperitoneal (i.p.) yolla sisplatin enjekte edildi. Cis+Q1030(n=8) grubuna tek bir14 mg/kg dozda i.p. sisplatin ve 3 gün boyunca günde 30 mg/kg dozdakoenzim Q10 i.p. enjekte edildi. Cis+Q1010(n=8) grubuna tek bir 14mg/kg dozda i.p. sisplatin ve 3 gün boyunca günde 10 mg/kg dozda koenzim Q10 i.p. enjekte edildi. Q10 (n=8) grubuna 3 gün boyunca günde 10 mg/kg dozda koenzim Q10 i.p. enjekte edildi. Kontrol grubuna(Grup C) (n=8) 3 gün boyunca günde 1 mL dozda i.p. salin enjekte edildi. Tedavi öncesi ve sonrası iflitme düzeyleri distorsiyon ürünü otoakustik emisyonlarla (DPOAE) değerlendirildi. Bulgular:Bafllangıca göre çalıflma sonunda 4004, 4358, 4761 ve 5188Hz'deki ölçüm sonuçlarında istatistiksel açıdan anlamlı herhangi birdeğifliklik yoktu (p>0.05). Diğer taraftan 5652, 6165, 7336 ve 7996Hz'deki ölçümlerde anlamlı bir farklılık vardı (sırasıyla p=0.002,p=0.037, p=0.001 ve p=0.001). Ayrıca 5652 Hz'deki değiflimin hızı Cisgrubunun Cis+Q1010, kontrol ve Q10 gruplarından farklı olduğunuortaya koydu (p

The effect of coenzyme Q10 on cisplatin-induced ototoxicity in rats

Objective:To determine the efficacy of systemic administration ofcoenzyme Q10 at low and high doses on cisplatin-induced ototoxicityin rats. Methods:Our study was performed with 40 Sprague-Dawley rats.They were divided randomly into five groups: Cis, Cis+Q1030,Cis+Q1010, Q10, and control. Cis (n=8) group was administered cisplatin[a single intraperitoneal (i.p.) injection of 14 mg/kg], Cis+Q1030(n=8)group was administered cisplatin (a single i.p. injection of 14 mg/kg) andcoenzyme Q10 (30 mg/kg/day, i.p.) for 3 days, Cis+Q1010(n=8) groupwas given cisplatin (a single dose of 14 mg/kg/day, i.p.) and coenzymeQ10 (10 mg/kg/day, i.p.) for 3 days, Q10 (n=8) group was administeredcoenzyme Q10 (10 mg/kg/day, i.p.) for 3 days and Group C (n=8) (control group) was administered saline solution (1 mL/day, i.p.) once dailyfor 3 days. Pretreatment and posttreatment hearing levels were evaluated with distortion product otoacoustic emissions (DPOAEs). Results: There was no statistically significant difference in the resultsof measurements of 4004, 4358, 4761 and 5188 Hz at end of the studyin comparison to baseline (p>0.05). On the other hand, there was a significant difference at the measurements of 5652, 6165, 7336 and 7996Hz (p=0.002, p=0.037, p=0.001, p=0.001, respectively). The rate ofchange at 5652 Hz revealed that Cis group was different fromCis+Q1010, control and Q10 groups (p<0.01); measurements at 6165Hz revealed that change at Cis group was significantly different fromcontrol and Q10 groups (p<0.01, p<0.05). Final measurements ofdecrease in Cis group at 7336 and 7996 Hz were significantly differentfrom baseline (p<0.05; p<0.01). Conclusion:The high-dose coenzyme Q10 showed a protective effecton hearing in cisplatin-induced ototoxicity while low-dose coenzymeQ10 protected hearing at low frequencies but did not show protectiveeffect at high frequencies.

PDF

___

1. Walker EM Jr, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990;10:323-54.
2. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995;76:386-94.
3. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007;137:747-52.
4. Rybak LP, Whitworth CA, Mukherjea D, Ramkuvar L. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157-67.
5. Van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006;32:390-7.
6. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D. Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol 2004;124:421-6.
7. Ise T, Shimizu T, Lee EL, Inoue H, Kohno K, Okada Y. Roles of volume-sensitive Cl-channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J Membr Biol 2005;205:139-45.
8. Van Ruijven MW, de Groot JC, Klis SF, Smoorenbug GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005;205:241-8.
9. Sergi B, Fetoni AR, Paludetti G, et al. Protective properties of idebenone in noise-induced hearing loss in the guinea pig. Neuroreport 2006;17:857-61.
10. Papucci L, Schiavone N, Witort E, et al. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278: 28220-8.
11. Hinojosa R, Riggs LC, Strauss M, Matz GJ. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995;16:731-40.
12. Hyppolito MA, de Oliveira JA, Rossato M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 2006;263:798-803.
13. Church MW, Blakley BW, Burgio DL, Gupta AK. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. J Assoc Res Otolaryngol 2004;5:227-37.
14. Korver KD, Rybak LP, Whitworth C, Campbell KM. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 2002;126:683-9.
15. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004;114:538-42.
16. Berkiten G, Salturk Z, Topalo¤lu I, U¤rafl H. Protective effect of pentoxifylline on amikacin-induced ototoxicity in rats. Am J Otolaryngol 2012;33:689-92.
17. Chen X, Frisina RD, Bowers WJ, Frisina DR, Federoff HJ. HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol Ther 2001;3:958-63.
18. So HS, Park C, Kim HJ, et al. Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear Res 2005;204:127-39.
19. Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000;28:73-80.
20. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000; 21:513-20.
21. Ahn JH, Yoo MH, Lee HJ, Chung JW, Yoon TH. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol 2010;35:486-9.
22. Hirose Y, Sugahara K, Mikuriya T, Hashimoto M, Shimogori H, Yamashita H. Effect of water-soluble coenzyme Q10 on noiseinduced hearing loss in guinea pigs. Acta Otolaryngol 2008;128:1071-6.
23. Guastini L, Mora R, Dellepiane M, Santamauro V, Giorgio M, Salami A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol 2011;131:512-7.
24. Fetoni AR, Eramo SL, Rolesi R, Troiani D, Paludetti G. Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012;32:103-10.
25. Sockalingam R, Freeman S, Cherny TL, Sohmer T. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol 2000;21:521-7.
26. Fetoni AR, Garzaro M, Ralli M, et al. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit 2009;15:PR1-8.